Constellium: The Spread Between Feedstock And End Prices Keeps Widening
Constellium is described as a Strong Buy, citing structural margin improvements and robust segment performance that led to raised guidance, with adjusted EBITDA now projected at $980M–$1.02B for 2026 and free cash flow above $300M, reflecting early achievement of 2028 targets.
Why it matters — A CSTM watcher would care because the raised 2026 guidance and early 2028 target attainment signal improved earnings and cash flow outlook ahead of prior expectations.